|
|
|
|
 |
| August 18, 2011 | ISSUE NUMBER 213 VOL 8 |
Special Feature
Pharma's Influence on the Super Committee:
Is Cash Really King?
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to new data. And Sen. Max Baucus (D-MT) received more pharma dollars than any other Super Committee member
...Read more
Regulatory
An Upward Trajectory for New Drug Approvals
Through the end of July, FDA’s Center for Drug Evaluation and Research had approved 21 new drugs (new molecular entities and new biologics license applications), which equals the total number of new drugs approved in all of 2010. Although not enough to claim a reversal of the recent downward trend in drug R&D productivity, the numbers are a good sign for the industry ...Read More
Economy
Congressional Investigations: What Every Pharm Exec
Should Know
Most executives are familiar with traditional government investigations. Congressional investigations, however, unfold differently and present disparate challenges than conventional grand jury investigations
...Read More
Safety
Pfizer Brings Quality-by-Design into the Spotlight
The quality-by-design (QbD) initiative posits that the better a company understands a product’s quality attributes, the more likely that product will be safe and efficacious ...Read more
|
|
|
 // Sanofi Pasteur (Swiftwater, Pa.) announced the appointment of Chad Hoover as Vice President and Chief Commercial Officer of Sanofi Pasteur US. // Mahmoud Ghazzi, MD, PhD, has joined Daiichi Sankyo Pharma Development (Edison, NJ) as its new executive vice president of drug development for the Americas region. //
Health Market Science (King of Prussia, Pa.) appointed Mark Cieplik as Senior Vice President of Life Sciences Sales.
//
Compliance Implementation Services (San Francisco) announced Kim Life as its Vice President of Commercial Compliance. |
|
|
|
|
|
 |
|
| |
|
 |
|
 |
| What should be the FDA's priorities in implementing the US biosimilar pathway? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
